Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guidance of Adjuvant Instillation in Intermediate Risk Non-muscle Invasive Bladder Cancer by Drug Screens in Patient Derived Organoids
NCT05024734Phase 2Active, not recruiting
- Start
- Feb 2023
- Primary completion
- Dec 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of epirubicin, mitomycin c, gemcitabine, docetaxel in Non-muscle-invasive bladder cancer (NMIBC). Started Feb 2023; status: active, not recruiting.
02
Drugs
epirubicinmitomycin cgemcitabinedocetaxel
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05024734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05024734.